---
document_datetime: 2025-12-09 23:23:57
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rasagiline-viatris.html
document_name: rasagiline-viatris.html
version: success
processing_time: 0.130513
conversion_datetime: 2025-12-28 15:47:24.955006
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Rasagiline Viatris (previously Rasagiline Mylan)

[RSS](/en/individual-human-medicine.xml/66380)

##### Authorised

This medicine is authorised for use in the European Union

rasagiline Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Rasagiline Viatris (previously Rasagiline Mylan)](#news-on)
- [More information on Rasagiline Mylan](#more-information-on-rasagiline-mylan-1296)
- [Related information](#related-information-684)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Rasagiline Viatris is a medicine used to treat adults with Parkinson's disease (a progressive brain disorder that causes shaking, slow movement and muscle stiffness).

Rasagiline Viatris can be used either alone, or as an add-on to levodopa (another medicine used in Parkinson's disease) in patients who are having fluctuations in the control of their condition. Fluctuations happen when the effects of the medication wear off and symptoms re-emerge before the next dose is due. They are linked to a reduction in the effect of levodopa, when the patient experiences sudden switches between being 'on' and able to move, and being 'off' and having difficulty moving about.

Rasagiline Viatris contains the active substance rasagiline and is a 'generic medicine'. This means that Rasagiline Viatris contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Rasagiline Viatris is Azilect. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Rasagiline Viatris used?

Rasagiline Viatris is available as tablets. The standard dose is one tablet once a day.

The medicine can only be obtained with a prescription.

For more information about using Rasagiline Viatris, see the package leaflet or contact your doctor or pharmacist.

## How does Rasagiline Viatris work?

The active substance in Rasagiline Viatris, rasagiline, is a 'monoamine oxidase B inhibitor'. It blocks the enzyme monoamine oxidase type B, which breaks down a substance called dopamine in the brain. Dopamine is important for controlling movement and coordination. In patients with Parkinson's disease, the cells that produce dopamine begin to die and the amount of dopamine in the brain decreases. The patients then lose their ability to control their movements reliably. By increasing levels of dopamine in the parts of the brain that control movement and coordination, Rasagiline Viatris reduces the symptoms of Parkinson's disease, such as stiffness and slowness of movement.

## How has Rasagiline Viatris been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Azilect, and do not need to be repeated for Rasagiline Viatris.

As for every medicine, the company provided studies on the quality of Rasagiline Viatris. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Rasagiline Viatris?

Because Rasagiline Viatris is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Rasagiline Viatris authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Rasagiline Viatris has been shown to have comparable quality and to be bioequivalent to Azilect. Therefore, the Agency's view was that, as for Azilect, the benefit outweighs the identified risk and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Rasagiline Viatris?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rasagiline Viatris have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Azilect also apply to Rasagiline Viatris where appropriate.

As for all medicines, data on the use of Rasagiline Viatris are continuously monitored. Suspected side effects reported with Rasagiline Viatris are carefully evaluated and any necessary action taken to protect patients.

## Other information about Rasagiline Viatris

Rasagiline Mylan received a marketing authorisation valid throughout the EU on 4 April 2016.

The name of the medicine was changed to Rasagiline Viatris on 29 July 2024.

Rasagiline Viatris : EPAR - Medicine overview

Reference Number: EMA/284772/2024

English (EN) (137.26 KB - PDF)

**First published:** 29/04/2016

**Last updated:** 08/01/2025

[View](/en/documents/overview/rasagiline-viatris-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-545)

български (BG) (154.85 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/bg/documents/overview/rasagiline-viatris-epar-medicine-overview_bg.pdf)

español (ES) (131.66 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/es/documents/overview/rasagiline-viatris-epar-medicine-overview_es.pdf)

čeština (CS) (152.21 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/cs/documents/overview/rasagiline-viatris-epar-medicine-overview_cs.pdf)

dansk (DA) (129.91 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/da/documents/overview/rasagiline-viatris-epar-medicine-overview_da.pdf)

Deutsch (DE) (134.71 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/de/documents/overview/rasagiline-viatris-epar-medicine-overview_de.pdf)

eesti keel (ET) (128.24 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/et/documents/overview/rasagiline-viatris-epar-medicine-overview_et.pdf)

ελληνικά (EL) (154.96 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/el/documents/overview/rasagiline-viatris-epar-medicine-overview_el.pdf)

français (FR) (133 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/fr/documents/overview/rasagiline-viatris-epar-medicine-overview_fr.pdf)

hrvatski (HR) (149.54 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/hr/documents/overview/rasagiline-viatris-epar-medicine-overview_hr.pdf)

italiano (IT) (129.74 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/it/documents/overview/rasagiline-viatris-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (158.74 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/lv/documents/overview/rasagiline-viatris-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (151.95 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/lt/documents/overview/rasagiline-viatris-epar-medicine-overview_lt.pdf)

magyar (HU) (124.05 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/hu/documents/overview/rasagiline-viatris-epar-medicine-overview_hu.pdf)

Malti (MT) (153.7 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/mt/documents/overview/rasagiline-viatris-epar-medicine-overview_mt.pdf)

Nederlands (NL) (131.77 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/nl/documents/overview/rasagiline-viatris-epar-medicine-overview_nl.pdf)

polski (PL) (154.17 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/pl/documents/overview/rasagiline-viatris-epar-medicine-overview_pl.pdf)

português (PT) (132.77 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/pt/documents/overview/rasagiline-viatris-epar-medicine-overview_pt.pdf)

română (RO) (149.1 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/ro/documents/overview/rasagiline-viatris-epar-medicine-overview_ro.pdf)

slovenčina (SK) (152 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/sk/documents/overview/rasagiline-viatris-epar-medicine-overview_sk.pdf)

slovenščina (SL) (148.81 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/sl/documents/overview/rasagiline-viatris-epar-medicine-overview_sl.pdf)

Suomi (FI) (128.43 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/fi/documents/overview/rasagiline-viatris-epar-medicine-overview_fi.pdf)

svenska (SV) (129.24 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

08/01/2025

[View](/sv/documents/overview/rasagiline-viatris-epar-medicine-overview_sv.pdf)

Rasagiline Mylan : EPAR - Risk-management-plan summary

English (EN) (101.16 KB - PDF)

**First published:** 25/01/2016

**Last updated:** 23/07/2021

[View](/en/documents/rmp-summary/rasagiline-mylan-epar-risk-management-plan-summary_en.pdf)

## Product information

Rasagiline Viatris : EPAR - Product Information

English (EN) (311.1 KB - PDF)

**First published:** 29/04/2016

**Last updated:** 01/12/2025

[View](/en/documents/product-information/rasagiline-viatris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-829)

български (BG) (452.43 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/bg/documents/product-information/rasagiline-viatris-epar-product-information_bg.pdf)

español (ES) (222.3 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/es/documents/product-information/rasagiline-viatris-epar-product-information_es.pdf)

čeština (CS) (325.65 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/cs/documents/product-information/rasagiline-viatris-epar-product-information_cs.pdf)

dansk (DA) (267.92 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/da/documents/product-information/rasagiline-viatris-epar-product-information_da.pdf)

Deutsch (DE) (192.33 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/de/documents/product-information/rasagiline-viatris-epar-product-information_de.pdf)

eesti keel (ET) (336.01 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/et/documents/product-information/rasagiline-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (280.39 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/el/documents/product-information/rasagiline-viatris-epar-product-information_el.pdf)

français (FR) (205.01 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/fr/documents/product-information/rasagiline-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (328.42 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/hr/documents/product-information/rasagiline-viatris-epar-product-information_hr.pdf)

íslenska (IS) (264.08 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/is/documents/product-information/rasagiline-viatris-epar-product-information_is.pdf)

italiano (IT) (121.25 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/it/documents/product-information/rasagiline-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (254.78 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/lv/documents/product-information/rasagiline-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (366.2 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/lt/documents/product-information/rasagiline-viatris-epar-product-information_lt.pdf)

magyar (HU) (447.82 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/hu/documents/product-information/rasagiline-viatris-epar-product-information_hu.pdf)

Malti (MT) (615.07 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/mt/documents/product-information/rasagiline-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (454.08 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/nl/documents/product-information/rasagiline-viatris-epar-product-information_nl.pdf)

norsk (NO) (287.84 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/no/documents/product-information/rasagiline-viatris-epar-product-information_no.pdf)

polski (PL) (181.94 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/pl/documents/product-information/rasagiline-viatris-epar-product-information_pl.pdf)

português (PT) (323.75 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/pt/documents/product-information/rasagiline-viatris-epar-product-information_pt.pdf)

română (RO) (343.65 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/ro/documents/product-information/rasagiline-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (433.09 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/sk/documents/product-information/rasagiline-viatris-epar-product-information_sk.pdf)

slovenščina (SL) (340.95 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/sl/documents/product-information/rasagiline-viatris-epar-product-information_sl.pdf)

Suomi (FI) (370.24 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/fi/documents/product-information/rasagiline-viatris-epar-product-information_fi.pdf)

svenska (SV) (275.71 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

01/12/2025

[View](/sv/documents/product-information/rasagiline-viatris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000314043 26/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Rasagiline Viatris : EPAR - All Authorised presentations

English (EN) (23.82 KB - PDF)

**First published:** 29/04/2016

**Last updated:** 22/07/2024

[View](/en/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-598)

български (BG) (52.78 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/bg/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_bg.pdf)

español (ES) (14.4 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/es/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_es.pdf)

čeština (CS) (48.66 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/cs/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (82.22 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/da/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (44.6 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/de/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (221.07 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/et/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (83.9 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/el/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_el.pdf)

français (FR) (15.77 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/fr/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (96.13 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/hr/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (80.23 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/is/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_is.pdf)

italiano (IT) (80.28 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/it/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (223.34 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/lv/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (224.88 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/lt/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (60.52 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/hu/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (62.52 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/mt/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (59.37 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/nl/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (63.56 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/no/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_no.pdf)

polski (PL) (23.89 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/pl/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_pl.pdf)

português (PT) (41.03 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/pt/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_pt.pdf)

română (RO) (47 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/ro/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (74.14 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/sk/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (39.57 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/sl/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (86.42 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/fi/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (63.12 KB - PDF)

**First published:**

29/04/2016

**Last updated:**

22/07/2024

[View](/sv/documents/all-authorised-presentations/rasagiline-viatris-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Rasagiline Viatris (previously Rasagiline Mylan) Active substance rasagiline tartrate International non-proprietary name (INN) or common name rasagiline Therapeutic area (MeSH) Parkinson Disease Anatomical therapeutic chemical (ATC) code N04BD02

### Pharmacotherapeutic group

Anti-Parkinson drugs

### Therapeutic indication

Rasagiline Viatris is indicated for the treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

## Authorisation details

EMA product number EMEA/H/C/004064

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Mulhuddart Dublin 15 Ireland

Opinion adopted 28/01/2016 Marketing authorisation issued 04/04/2016 Revision 11

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Rasagiline Viatris : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.64 KB - PDF)

**First published:** 22/07/2024

**Last updated:** 01/12/2025

[View](/en/documents/procedural-steps-after/rasagiline-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Rasagiline Mylan : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (160.91 KB - PDF)

**First published:** 22/06/2016

**Last updated:** 13/05/2024

[View](/en/documents/procedural-steps-after/rasagiline-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Rasagiline Mylan : EPAR - Public assessment report

Adopted

Reference Number: EMA/282791/2016

English (EN) (420.96 KB - PDF)

**First published:** 29/04/2016

**Last updated:** 29/04/2016

[View](/en/documents/assessment-report/rasagiline-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Rasagiline Mylan

Adopted

Reference Number: EMA/CHMP/23731/2016

English (EN) (67.36 KB - PDF)

**First published:** 29/01/2016

**Last updated:** 29/01/2016

[View](/en/documents/smop-initial/chmp-summary-opinion-rasagiline-mylan_en.pdf)

#### News on Rasagiline Viatris (previously Rasagiline Mylan)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 January 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-january-2016) 29/01/2016

#### More information on Rasagiline Mylan

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-517)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/search?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-1=1=EMEAHC0040640000) (initial marketing authorisation)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 01/12/2025

## Share this page

[Back to top](#main-content)